Literature DB >> 856008

In vitro activity of cinoxacin, ampicillin, and chloramphenicol against Shigella and nontyphoid Salmonella.

E Rubinstein, B Shainberg.   

Abstract

The in vitro antibacterial activity of cinoxacin was compared with that of ampicillin and chloramphenicol against 26 strains of nontyphoid Salmonella and 44 strains of Shigella. Cinoxacin was found to have a lower minimal inhibitory concentration than ampicillin and chloramphenicol against all Salmonella and Shigella sonnei strains. Cinoxacin had minimal inhibitory concentrations similar to those of chloramphenicol but lower than those of ampicillin against Shigella flexneri and S. boydii strains.

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 856008      PMCID： PMC352030          DOI： 10.1128/AAC.11.4.577

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  5 in total

1.  Comparative efficacy of nalidixic acid and ampicillin for severe shigellosis.

Authors:  K C Haltalin; J D Nelson; H T Kusmiesz
Journal:  Arch Dis Child       Date:  1973-04       Impact factor: 3.791

2.  Compound 64716, a new synthetic antibacterial agent.

Authors:  W E Wick; D A Preston; W A White; R S Gordee
Journal:  Antimicrob Agents Chemother       Date:  1973-10       Impact factor: 5.191

3.  Treatment of sonne dysentery.

Authors:  P J Moorhead; H E Parry
Journal:  Br Med J       Date:  1965-10-16

4.  Efficacy of cinoxacin in urinary tract infections.

Authors:  A P Panwalker; H Giamarellou; G G Jackson
Journal:  Antimicrob Agents Chemother       Date:  1976-03       Impact factor: 5.191

5.  Oxolinic acid in the treatment of typhoid fever due to chloramphenicol-resistant strains of Salmonella typhi.

Authors:  J P Sanford; N N Linh; E Kutscher; K Arnold; K Gould
Journal:  Antimicrob Agents Chemother       Date:  1976-03       Impact factor: 5.191
  5 in total
  1 in total

Review 1.  Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections.

Authors:  T S Sisca; R C Heel; J A Romankiewicz
Journal:  Drugs       Date:  1983-06       Impact factor: 9.546
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.